Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Pfizer has reported quarterly financial results that exceeded market expectations, contributing to a rise in its stock price. According to reports from Barron's, the company experienced a massive 95% plunge in revenue specifically tied to its Covid pill. However, this decline was offset by strengths in other areas of the business. Coverage from the Wall Street Journal indicates that the quarterly results beat expectations due to the performance of the company's cancer and heart drugs. Specifically, CNBC notes that Pfizer has hiked the low end of its revenue guidance, citing the strength of Eliquis and other pharmaceutical products. Multiple financial news outlets are tracking these developments, with Reuters reporting that Pfizer beat earnings estimates.
The coverage highlights a strategic shift toward operational efficiency, as Reuters specifies that the company is now targeting $2.5 billion in additional cost cuts. Bloomberg.com focuses on the company's forward-looking outlook, reporting that Pfizer has raised its sales guidance. This upward adjustment is attributed to high demand for older drugs within the company's portfolio. The collective reporting across these five sources suggests a transition from pandemic-era revenue streams toward a more diversified product base. To understand the current market reaction, it is necessary to note the volatility of the company's Covid-related income. While the Covid pill revenue collapse was steep, the company's ability to leverage its existing catalog of heart and cancer treatments has provided a buffer.
The focus of investors has shifted from the loss of pandemic-driven gains to the stability of established drugs and the potential for further margin improvement through the mentioned cost-cutting initiatives. This context explains why the stock is lifting despite the significant loss in a primary high-profile product line. Future developments will center on whether Pfizer can achieve the $2.5 billion in additional cost cuts reported by Reuters. Market observers will also be monitoring the actual sales figures for the older drugs and heart medications like Eliquis that prompted the raised guidance mentioned by Bloomberg.com and CNBC. Since the company has adjusted its revenue guidance upward, the next quarterly report will reveal if the demand for these non-Covid treatments continues to outpace the decline in pandemic-related sales. There is currently no information regarding specific new drug launches, only the strength of existing products.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 105d ago.
Quick answers
How much did Pfizer's Covid pill revenue decline?
According to Barron's, revenue from the Covid pill plunged by 95%.
What is driving Pfizer's increased revenue guidance?
Bloomberg.com and CNBC report that the guidance was raised due to high demand for older drugs and the strength of products such as Eliquis.
What cost-cutting measures is Pfizer implementing?
Reuters reports that Pfizer is targeting $2.5 billion in additional cost cuts.
Coverage (9)
- Pfizer expands multibillion-dollar cost-cutting plan BioPharma Dive · 105d ago
- Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics Yahoo Finance · 105d ago
- Pfizer repels Covid-19 sales tumble to raise 2026 guidance finance.yahoo.com · 105d ago
- Pfizer unveils additional $2.5B in planned cost savings through 2029 Fierce Pharma · 105d ago
- Pfizer Raises Sales Guidance on High Demand for Older Drugs Bloomberg.com · 105d ago
- Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts Reuters · 105d ago
- Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs WSJ · 105d ago
- Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs CNBC · 105d ago
- Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway. Barron's · 105d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Qualcomm Gives Tepid Profit Outlook After Supply Costs Rise
Qualcomm shares slide in afterhours trading as rising supply costs and smartphone market weakness cloud its growth outlook.